tapentadol (CG5503) ER

DRUG2 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions

Low Back PainLower Back PainOsteoarthritis, HipOsteoarthritis, KneePain

Phase 3

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

CompletedNCT00361504

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Lower Back Pain, Osteoarthritis, Hip, Osteoarthritis, Knee +1

Start: 2006-11-30End: 2008-07-31Updated: 2014-04-29

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

CompletedNCT00449176

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Low Back Pain

Start: 2007-02-28End: 2008-05-31Updated: 2012-04-30

Related Papers

Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.

2015-10-0134 citations

Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.

2015-09-0124 citations

Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis.

2014-08-0113 citations

A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.

2013-09-015 citations

Efficacy of tapentadol ER for managing moderate to severe chronic pain.

2013-01-0141 citations

Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain.

2010-09-01127 citations